On July 7, 3SBio fell 5.24% in regular trading, trading at HK$18.44/share, with turnover of HK$387 million. The decline came amid broad-based selling pressure across the biotechnology sector.

Within the Biotechnology sector where 3SBio belongs, individual stocks were broadly weaker. Among peers, Remegen fell 6.6%, Akeso fell 4.37%, Innovent Bio fell 3.48%, BeiGene fell 2.83%, and SKB Bio fell 2.2%. Earlier sector analysis from CITIC Construction Investment noted that the biopharmaceutical sector had been tracking the overall pharmaceutical industry pullback, likely related to capital and funding rotation factors.

Notably, 3SBio had risen 7.77% in the prior session on July 3, supported by innovative drug payment reform catalysts and a series of share buybacks totaling approximately 8.52 million shares in June. The current pullback partially reverses those recent gains.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)